Status:
COMPLETED
Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.
Eligibility Criteria
Inclusion
- Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years
- RA disease onset after 16 years of age and has had the disease for at least 6 months
- Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months
Exclusion
- Evidence of unstable clinically significant disease
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00440492
Start Date
December 1 2006
End Date
November 1 2007
Last Update
December 13 2007
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles, California, United States, 90048
2
Palo Alto, California, United States, 94304
3
Lake Success, New York, United States, 11042
4
Rochester, New York, United States, 14642